Skip to main content

Table 3 Comparison of GMTs, GMIs and seroconversion rates of poliovirus type-specific neutralizing antibodies after vaccination between maternal antibody negative and positive participants

From: The effect of maternal poliovirus antibodies on the immune responses of infants to poliovirus vaccines

Group

Type

GMT (95% CI)

GMI (95% CI)

Seroconversion rate (%)

Maternal negative

Maternal positive

P

Maternal negative

Maternal positive

P

Maternal negative

Maternal positive

P

1

I

5086.27 (3909.17–6617.80)

3191.30 (2619.36–3888.12)

0.006

1271.57 (977.29–1654.45)

111.56 (81.88–152.00)

< 0.001

100.00

98.78

1.000

II

878.35 (704.86–1094.54)

505.09 (381.51–668.70)

0.002

219.59 (176.21–273.63)

24.32 (15.51–38.11)

< 0.001

100.00

85.71

0.008

III

1142.55 (961.97–1357.03)

619.06 (386.93–990.46)

0.017

285.64 (240.49–339.26)

31.13 (15.56–62.31)

< 0.001

100.00

82.76

0.001

2

I

4231.17 (3210.69–5576.00)

3139.05 (2554.03–3858.08)

0.084

1057.79 (802.67–1394.00)

111.75 (88.66–154.84)

< 0.001

100.00

98.98

1.000

II

900.64 (767.91–1056.30)

550.11 (405.38–746.52)

0.005

225.16 (191.98–264.07)

30.25 (18.80–48.67)

< 0.001

100.00

90.70

0.023

III

1036.17 (880.40–1219.50)

564.94 (372.86–855.96)

0.003

259.04 (220.10–304.87)

29.60 (12.55–69.80)

< 0.001

100.00

86.96

0.006

3

I

6187.48 (4563.25–8389.85)

4131.94 (3411.86–5003.98)

0.025

1546.87 (1140.81–2097.46)

123.79 (86.99–176.17)

< 0.001

100.00

96.67

0.556

II

1018.74 (873.77–1187.76)

711.84 (567.01–893.67)

0.008

254.69 (218.44–296.94)

43.10 (29.34–63.29)

< 0.001

100.00

95.65

0.129

III

1207.23 (1025.79–1420.76)

835.86 (475.52–1469.29)

0.206

301.81 (256.45–355.19)

27.66 (10.49–72.96)

< 0.001

100.00

85.71

0.004

4

I

5830.71 (4431.70–7671.36)

3051.49 (2523.95–3689.29)

0.001

1457.68 (1107.92–1917.84)

88.46 (64.22–121.86)

< 0.001

100.00

95.83

0.574

II

273.86 (225.62–332.42)

228.21 (171.48–303.71)

0.276

68.47 (56.41–83.10)

16.22 (11.10–23.71)

< 0.001

100.00

89.36

0.014

III

675.19 (561.49–811.92)

260.20 (178.35–379.61)

< 0.001

168.80 (140.37–202.98)

11.08 (6.12–20.05)

< 0.001

100.00

84.85

0.001

5

I

546.12 (408.61–729.91)

660.98 (549.64–794.86)

0.306

136.53 (102.15–182.48)

19.40 (14.51–25.95)

< 0.001

100.00

88.42

0.122

II

209.42 (176.39–248.63)

122.10 (97.10–153.55)

< 0.001

52.35 (44.10–62.16)

7.62 (5.36–10.82)

< 0.001

100.00

78.26

< 0.001

III

501.89 (417.41–603.47)

567.52 (397.01–811.27)

0.518

125.47 (104.35–150.87)

36.94 (24.12–56.56)

< 0.001

100.00

100.00

  1. Group 1: low-dose Sabin IPV group. Group 2: medium-dose Sabin IPV group. Group 3: high-dose Sabin IPV group. Group 4: control Sabin IPV group. Group 5: control Salk IPV group